Evolution Biotechnologies announces the appointment of Panda New Capital of Beijing as global financial advisor to the company

Bedford, UK, March 18th 2020

Evolution Biotechnologies (www.evolutionbiotech.com), the UK-based company pioneering the use of biological control to benefit human health, today reports the appointment of Panda New Capital (PNC) and its partners as global financial advisors to the company.

Evolution has been working with Panda New Capital (PNC) since late 2019 and has agreed to expand the roles of PNC and its partner companies from Asian markets to a global role.

Dr. David Harper, Evolution’s CEO, said “we see expansion into Asia as a key priority for the company and we have found working with Panda New Capital to be highly productive. Based on results to date we are delighted to expand our involvement with PNC and look forward to working with them in wider global markets.”

Annie Han, President of Panda New Capital said “according to authoritative data, the import of asthma drugs and technology is an important direction. Evolution Biotechnologies’ patent as an international application of advanced biotechnology would fit well with the huge market demand in China.”

About Evolution Biotechnologies

Evolution Biotechnologies (UK company 09473027) is working to extend the application of biological control from its proven efficacy in agriculture into biomedical markets. The company’s initial targetis the development of a novel, self-amplifying biological control forthe house dust mite, an expanding multi-billion dollar market with high value and significant unmet need. Asthma is a worldwide, chronic disease and house dust mite allergens are key to both sensitization and the triggering of attacks. The number of asthma patients worldwide exceeds 330 million of whom approximately 20% require frequent hospitalization. 383,000 people every year die as a result of asthma. The costs of asthma exceed $100 billion in the EU and US alone.

About Panda New Capital

Panda New Capital (PNC) is a global boutique investment firm, part of the new trend of Chinese capital. PNC has an accurate understanding of the Chinese economy and investment structures. It has a team with an extensive background in global capital markets on healthcare, energy and hightechnology. Since there is still a big gap between China and the world. The gap gives PNC a space to engage and share its investor resources, investment experiences and research capabilities. It’s strong and rich Chinese investor network is a great support for its foreign partners to reach objectives faster and more effectively.

Forward-looking statements

Panda New Capital (PNC) is a global boutique investment firm, part of the new trend of Chinese capital. PNC has an accurate understanding of the Chinese economy and investment structures. It has a team with an extensive background in global capital markets on healthcare, energy and hightechnology. Since there is still a big gap between China and the world. The gap gives PNC a space to engage and share its investor resources, investment experiences and research capabilities. It’s strong and rich Chinese investor network is a great support for its foreign partners to reach objectives faster and more effectively.

About biological control

Biological control is highly specific in nature, and is perceived as environmentally friendly. The US Environmental Protection Agency (EPA) has stated that “Since biopesticides tend to pose fewer risks than conventional pesticides, EPA generally requires much less data to register a biopesticide”.Biological control methodologies have been extensively used in the agricultural and food safety sectors and provide a “green” alternative to existing chemical approaches, especially where there are concerns over toxicity or resistance. Despite the validated route through the regulatory process and onto the market, application in the domestic and medical settings has received only limited attention to date. Evolution’s work is leading this important expansion of this proven approach into high value markets with unmet clinical need.

Forward-looking statements

This document contains certain forward-looking statements – i.e. statements that are not historical facts, including statements about our beliefs and expectations. These statements are based on plans, estimates and projections at the time we make the statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement.

Media contacts:

Email: pr@evolutionbiotech.com

Website: www.evolutionbiotech.com